Pepvise
Compound profile· Compounds

IGF-1 LR3, what the evidence shows

By The PepVise Editorial Team · Reviewed July 13, 2026 · 13 min read

Evidence Ledger for IGF-1 LR3 (Long R3 IGF-1), an engineered, binding-protein-resistant analog of insulin-like growth factor 1 used as a lab reagent and sold for muscle growth, with no human trials and no FDA approval. What the studies show, and what they do not.

We describe what has been measured, by whom, at what scale, with what effect size, and with what caveats. Hedging, here, is honesty.
The PepVise Editorial Teamfrom the house style guide
Editorial reference
Primary literature

PubMed saved search, 'long R3 IGF-I'

IGF-1 LR3 is a compound where the literature itself tells the story: search it and you find animal infusion studies, cell-culture reagent work and analytical papers on black-market samples, but no clinical trials in humans. A saved search makes that absence visible directly, more honestly than any summary, including ours, and it separates the genuine cell and animal pharmacology from the physique marketing built on top of it.

Reference reading

The texts we read alongside the papers.

  1. 01
    Primary literature

    PubMed saved search, 'long R3 IGF-I'

    A PubMed search surfaces the defining pattern: the Long R3 IGF-I literature is dominated by animal infusion studies, cell-culture reagent work and analytical papers on seized products, with no clinical trials in humans. It is the fastest way to see that the muscle-building claims run well ahead of anything measured in people.

  2. 02
    Reference text

    Williams Textbook of Endocrinology (14th ed.)

    The growth hormone and IGF-1 axis is standard endocrinology, including the binding proteins, the feedback loops and the receptor biology that make IGF signaling self-regulating. Williams supplies the physiology needed to read the potency and mechanism claims critically, without the performance-marketing layer that vendor and forum pages add.

  3. 03
    Popular-science background

    Outlive, Peter Attia, MD (with Bill Gifford)

    Attia's distinction between an approved indication backed by endpoint data and an extrapolated performance claim is exactly the discipline IGF-1 LR3 requires, since its only human-relevant approval is for a rare pediatric deficiency of the natural molecule. It does not cover the analog directly; the reasoning framework is the point.

Methodology

How we read the literature

Evidence tier
We grade the literature on four tiers, High (replicated RCTs or meta-analyses), Moderate (multiple trials with mixed findings), Low (a single pilot or case series), and Anecdotal (preclinical only, no human data). The tier appears on every compound profile beside the claim it supports.
Trial stage
Where a compound sits in the human development pipeline is recorded as Preclinical, Phase 1, Phase 2, or Phase 3+. We pull the current stage from ClinicalTrials.gov and the EU Clinical Trials Register on access date and re-verify quarterly.
Regulatory status
We state the FDA posture plainly, approved for indication X, or labeled for research use only, or removed from the 503A list, or investigational under a specific IND. Regulatory status changes; every post carries a review date.
Where we're uncertain
Every compound profile closes with a named uncertainty section, the question we can't answer from the current literature, the trial we'd want to see, the effect size we'd treat as a real signal. Uncertainty is not a failure mode here; it's load-bearing.
Frequently asked

The questions readers actually bring us.

Is IGF-1 LR3 FDA-approved?
No. IGF-1 LR3 is an engineered research analog with no FDA-approved indication, sold as a research chemical labeled for non-human use. Native recombinant IGF-1, mecasermin (Increlex), is FDA-approved, but only for severe primary IGF-1 deficiency in children, and that approval does not extend to the more potent Long R3 analog.
What is the difference between IGF-1 LR3 and regular IGF-1?
Long R3 IGF-1 carries a 13-amino-acid N-terminal extension and a single substitution at position 3, arginine in place of glutamate. Those changes make it resist the IGF binding proteins that normally restrain IGF-1, so it stays free, lasts longer and is markedly more potent than the natural molecule in cell and animal models.
Does IGF-1 LR3 build muscle?
There are no human trials to say. In cell culture and some animal studies it is potently pro-growth, but those results do not establish safe muscle gain in healthy people, and animal work shows the body suppresses its own IGF-1 and growth hormone in response, which complicates the picture. The muscle claims are extrapolation, not demonstrated human outcomes.
Is IGF-1 LR3 safe?
Its safety in humans is unknown because no clinical trials exist. Known concerns from IGF biology include hypoglycemia, because it overlaps with insulin signaling, and the theoretical risk that sustained IGF-1 receptor activation promotes the growth of existing tumors. Black-market products are also frequently impure or mislabeled, adding an unpredictable risk on top of the biology.
Why does PepVise not give an IGF-1 LR3 dose?
Because we describe the literature and do not recommend administration. IGF-1 LR3 was created as a laboratory reagent, no human dose-finding trials exist, and the figures repeated on forums are not derived from controlled studies. We explain how these research chemicals are regulated separately.
What would change our reading

A Phase 2 randomized trial with blinded outcome assessment would change the reading. A new independent replication outside the currently dominant research group would change the reading. A regulatory action, approval, restriction, or a class warning, would change the reading. When any of those lands, we update this profile within a week and mark what changed.

The masthead

About The Pepvise Editorial Team

The Pepvise Editorial Team is a small group of researchers and science writers reading the peer-reviewed peptide literature and translating it into calm, cited analysis. We do not sell peptides, recommend peptides, or tell readers what to administer. We describe what has been measured, by whom, at what scale, with what effect size.

Compound reviews are signed off by Dr. Priya Narang, MD, MPH (endocrinologist) and Dr. Marcus Haley, PharmD, BCPS (board-certified clinical pharmacist). Both hold verifiable state-board licenses and have signed editorial-independence letters with us. See the full editorial board →

Further reading

Adjacent in the literature.

Compounds · Compound profile

BPC-157, What the Evidence Shows

Evidence Ledger for BPC-157: 50+ preclinical studies, 1 human pilot (Chang 2014, n=12), 1 active Phase trial, FDA removed from 503A list in 2023.

16 min readCompounds · Compound profile

TB-500, The Field Guide

TB-500 vs Thymosin Beta-4 (same compound), mechanism, the preclinical tendon and recovery literature, and where the human data is thin.

14 min readCompounds · Compound profile

GHK-Cu, Evidence and Hype

Copper peptide signaling, the topical RCT evidence for hair and skin, and the gap between topical and injectable claims.

13 min read

Get the 2026 Peptide Evidence Ledger.

A 12-page PDF summary of where 10 major compounds sit, Preclinical / Human pilot / Phase trial / FDA status. Updated quarterly. Free.

By subscribing, you agree to our Privacy Policy. One calm, cited email a week. Unsubscribe anytime.